<DOC>
	<DOCNO>NCT00714597</DOCNO>
	<brief_summary>The primary objective compare efficacy daily [ q.d ] subcutaneous [ s.c. ] injection Semuloparin sodium ( AVE5026 ) q.d . s.c. injection Enoxaparin primary prevention Venous Thromboembolic Events [ VTE ] patient hospitalize acute medical illness . The secondary objective evaluate safety AVE5026 document AVE5026 exposure population .</brief_summary>
	<brief_title>Evaluation AVE5026 Prevention Venous Thromboembolism Acutely Ill Medical Patients With Restricted Mobility</brief_title>
	<detailed_description>Randomization take place prior first study drug injection . The total duration observation per participant 35-42 day randomization broken follow : - 10 14-day double-blind treatment period ; - 25 32-day follow-up period . Mandatory bilateral compression ultrasound [ CUS ] perform 10 15 day randomization .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>Patient acute medical condition require bed rest least 3 day , hospitalize least one follow medical condition : Congestive heart failure ( New York Heart Association [ NYHA ] class III/IV ) ; Acute respiratory failure ( require mechanical ventilation ) ; Acute infection ( without septic shock ) * ; Acute rheumatic disorder* ; Acute episode inflammatory bowel disease* . Patient one condition least one additional risk factor venous thromboembolism ( VTE ) among follow : Age â‰¥ 75 year ; Active cancer myeloproliferative disorder ( receive treatment cancer within last 6 month ) ; Previous VTE ; Obesity ; Oral hormone therapy ( antiandrogen estrogen ) ; Chronic heart failure ; Chronic respiratory failure . Previous surgery general anesthesia within 30 day inclusion study ; Patient require curative anticoagulant thrombolytic treatment ; Patient risk bleeding ; Stroke ; Known hypersensitivity heparin enoxaparin sodium ; End stage renal disease patient dialysis . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Venous thrombosis</keyword>
	<keyword>Primary prevention</keyword>
</DOC>